GHK-Cu Research Findings by Application Area: Dermal, Wound, and Other Models

For laboratory research use only. This article summarises publicly available research literature on GHK-Cu by model system, provided for reference. It is not medical, veterinary, cosmetic, or dosing guidance and makes no health, therapeutic, or outcome claims. Nothing described here is for human or animal use.

GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) has one of the broadest literatures of any short peptide — dermal models, wound models, follicle models, and a scattering of organ-system work. Breadth is not the same as depth, and the evidence is far stronger in some of those areas than others. This article organises what has actually been examined, by application area, and says where the data thins out.

1. Origins

In 1973 the biochemist Loren Pickart was studying ageing in human blood and liver tissue and observed that old liver cells exposed to plasma from younger donors began functioning differently. Isolating the responsible fraction produced a tripeptide — glycine, histidine, lysine — bound to a copper ion. Our account of the discovery covers the plasma-fractionation work in detail.

The age-related decline

Published figures put plasma GHK-Cu at roughly 200 ng/mL in the early twenties, declining to roughly 80 ng/mL by age 60. That decline is the observation the entire subsequent literature was built around.

Naturally occurring versus synthesised material

The GHK-Cu used in research today is chemically synthesised and identical in sequence and coordination to the plasma-derived molecule. What differs between sources is not the molecule but its purity and the presence of synthesis-related impurities — which is why identity and purity confirmation, not provenance claims, is the thing worth checking.

2. Gene expression: the mechanism underneath the breadth

Why a single tripeptide appears across so many model systems is best explained by gene-expression work. Profiling using the Broad Institute’s Connectivity Map reported that GHK modulates expression of roughly 4,000 human genes — upward for genes associated with repair, antioxidant systems and matrix synthesis, downward for genes associated with chronic inflammation and tissue destruction.

That is a plausible mechanistic explanation for range, and it is also why findings in one model system should not be read as predictive of another. A shared upstream mechanism does not make dermal results transferable to lung results.

3. Dermal models

The dermal literature is the largest of the application areas.

Matrix protein synthesis

Reported findings associate GHK-Cu exposure with synthesis of:

• Type I collagen — the most abundant collagen, providing tensile strength.
• Type III collagen — predominant in early-life tissue.
• Elastin — the protein responsible for elastic recoil.
• Glycosaminoglycans — water-binding matrix molecules.

Dermal thickness measurements

A frequently cited 12-week study applied a GHK-Cu-containing cream to photoaged facial skin, with ultrasound measurement of dermal thickness as the endpoint; increased thickness was the reported result. Endpoint choice matters when reading this literature — ultrasound-measured thickness is a physical measurement, which is a different class of evidence from a visual assessment score.

How the mechanism differs from retinoids

Retinoid literature centres on accelerated cell turnover. GHK-Cu literature centres on matrix remodelling and inflammatory-marker modulation. These are mechanistically different pathways studied against different endpoints, and comparisons between them are only meaningful when the endpoint is held constant. Our comparison of GHK-Cu against other copper peptides in dermal research covers how the dermal endpoints are set up.

4. Wound models

Wound repair proceeds in phases, and the reported role of GHK-Cu differs at each:

The remodelling-phase findings are the most distinctive: degradation of disorganised matrix and synthesis of new matrix are reported together rather than sequentially, which is the mechanism most often cited in scar-model work.

Stalled-wound models

Chronic non-healing wound models — including diabetic ulcer models — are characterised by wounds arrested in the inflammatory phase. Published work in this area reports transition out of that phase, with the angiogenesis findings offered as the mechanistic explanation for why ischemic tissue responds at all. This is model-system research; it establishes nothing about clinical practice.

5. Hair follicle models

This line of research opened when animals treated with GHK-Cu in wound studies were observed to grow hair around the injury site. Follicle-model findings reported since include:

• Follicle size — biopsies reporting enlargement of miniaturised follicles.
• Anagen duration — action on dermal papilla cells associated with a longer growth phase.
• Perifollicular vascularisation — the same angiogenesis mechanism reported in wound models.
• 5-alpha reductase — some studies suggest local inhibition of the enzyme converting testosterone to DHT.

The follicle literature is smaller and more heterogeneous than the dermal literature, and the studies differ enough in preparation and endpoint that cross-study comparison is difficult.

6. Other model systems

Beyond skin, wounds, and follicles, GHK-Cu appears in a scattered set of organ-system studies. These are early and mostly in-vitro or animal work.

Neurological models

Reported findings include downregulation of fibrinogen-synthesis genes, association with neurotrophic factor expression, and reduced inflammatory markers in ageing animal models. This is a small literature at an early stage.

Lung fibroblast models

Genomic work reported that GHK-Cu exposure shifts the gene-expression signature of COPD-associated lung fibroblasts, and in-vitro work on human lung fibroblasts reported restored contraction and matrix-remodelling behaviour. Animal acute-lung-injury models reported reduced inflammatory cytokine signalling and less fibrotic tissue change.

Antioxidant systems

GHK-Cu is reported to act on endogenous antioxidant systems — notably upregulating superoxide dismutase (SOD) — rather than by directly scavenging free radicals itself. That is a mechanistically distinct behaviour from a conventional antioxidant and is one of the more consistently reproduced findings in the corpus.

Reading this literature honestly

The volume of GHK-Cu research is genuinely unusual for a tripeptide, and it is also unevenly distributed. Dermal and wound models carry the most data; follicle work is moderate; neurological, pulmonary and other organ-system work is early. Findings do not transfer between model systems, and nothing in this corpus concerns use in humans.

Verifying the material

None of the above is meaningful unless the material in the vial is what the label says. Look for mass-spectrometry identity confirmation and an HPLC purity trace with a sharp main peak from independent third-party testing. GHK-Cu is also supplied in blended research material such as KLOW 80mg, which pairs it with TB-500. Testing records are published in our COA archive, and how to read an HPLC chromatogram covers what the trace shows.

For laboratory and research use only. Not for human consumption. Nothing here is intended for human or animal use. All materials referenced are supplied strictly for in-vitro and other controlled preclinical research by qualified professionals and are third-party tested for identity and purity.